Muhammad Hussain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammad Hussain has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Anjali Seth
Molecular Pathology Laboratory, Fox Chase Cancer Center, Department of Pathology Genomic Cancer Institute Philadelphia Pennsylvania USA
2 shared publications - Bhaumik Shah
Department of Pathology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA 19121, USA
2 shared publications
Latest Publications
- Open Access
- 8 August 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (8) , 638
Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment
Homologous recombination deficiency (HRD) is a pivotal biomarker in precision oncology, driving therapeutic strategies for ovarian and breast cancers through impaired DNA double-strand break repair. This narrative review synthesizes recent advances (2021–2025) in HRD’s biological basis, prevalence, detection methods, and clinical implications, focusing on high-grade serous ovarian carcinoma (HGSOC; ~50% HRD prevalence) and triple-negative breast cancer (TNBC; 50–70% prevalence). HRD arises from genetic (BRCA1/2, RAD51C/D, PALB2) and epigenetic alterations (e.g., BRCA1 methylation), leading to genomic instability detectable via scars (LOH, TAI, LST) and mutational signatures (e.g., COSMIC SBS3). Advanced detection integrates genomic assays (Myriad myChoice CDx, Caris HRD, FoundationOne CDx), functional assays (RAD51 foci), and epigenetic profiling, with tools like HRProfiler and GIScar achieving >90% sensitivity. HRD predicts robust responses to PARP inhibitors (PARPi) and platinum therapies, extending progression-free survival by 12–36 months in HGSOC. However, resistance mechanisms (BRCA reversion, SETD1A/EME1, SOX5) and assay variability (60–70% non-BRCA concordance) pose challenges. We propose a conceptual framework in Section 10, integrating multi-omics, methylation analysis, and biallelic reporting to enhance detection and therapeutic stratification. Regional variations (e.g., Asian cohorts) and disparities in access underscore the need for standardized, cost-effective diagnostics. Future priorities include validating novel biomarkers (SBS39, miR-622) and combination therapies (PARPi with ATR inhibitors) to overcome resistance and broaden HRD’s applicability across cancers.
- 8 August 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (8) , 638
Open AccessHomologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment
Homologous recombination deficiency (HRD) is a pivotal biomarker in precision oncology, driving therapeutic strategies for ovarian and breast cancers through impaired DNA double-strand break repair. This narrative review synthesizes recent advances (2021–2025) in HRD’s biological basis, prevalence, detection methods, and clinical implications, focusing on high-grade serous ovarian carcinoma (HGSOC; ~50% HRD prevalence) and triple-negative breast cancer (TNBC; 50–70% prevalence). HRD arises from genetic (BRCA1/2, RAD51C/D, PALB2) and epigenetic alterations (e.g., BRCA1 methylation), leading to genomic instability detectable via scars (LOH, TAI, LST) and mutational signatures (e.g., COSMIC SBS3). Advanced detection integrates genomic assays (Myriad myChoice CDx, Caris HRD, FoundationOne CDx), functional assays (RAD51 foci), and epigenetic profiling, with tools like HRProfiler and GIScar achieving >90% sensitivity. HRD predicts robust responses to PARP inhibitors (PARPi) and platinum therapies, extending progression-free survival by 12–36 months in HGSOC. However, resistance mechanisms (BRCA reversion, SETD1A/EME1, SOX5) and assay variability (60–70% non-BRCA concordance) pose challenges. We propose a conceptual framework in Section 10, integrating multi-omics, methylation analysis, and biallelic reporting to enhance detection and therapeutic stratification. Regional variations (e.g., Asian cohorts) and disparities in access underscore the need for standardized, cost-effective diagnostics. Future priorities include validating novel biomarkers (SBS39, miR-622) and combination therapies (PARPi with ATR inhibitors) to overcome resistance and broaden HRD’s applicability across cancers.
- Open Access
- 3 April 2025
- Published by MDPI AG in Preprints.org
Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and Treatment
Homologous recombination deficiency (HRD) is a pivotal biomarker in oncology, influencing treatment strategies and prognostic assessments. HRD impairs DNA repair mechanisms, leading to genomic instability and heightened sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, particularly in ovarian and breast cancers. This review examines the molecular basis of HRD, current methodologies for its detection, and its clinical relevance in precision oncology. We address challenges in standardizing HRD assessment, including variability in testing approaches and interpretation thresholds. Additionally, emerging strategies for optimizing HRD-targeted therapies are discussed, emphasizing novel biomarkers and therapeutic combinations. By consolidating current knowledge and advancements, this review provides insights into HRD’s role in cancer biology and its potential for refining personalized treatment approaches.
- 3 April 2025
- Published by MDPI AG in Preprints.org
Open AccessHomologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and Treatment
Homologous recombination deficiency (HRD) is a pivotal biomarker in oncology, influencing treatment strategies and prognostic assessments. HRD impairs DNA repair mechanisms, leading to genomic instability and heightened sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors, particularly in ovarian and breast cancers. This review examines the molecular basis of HRD, current methodologies for its detection, and its clinical relevance in precision oncology. We address challenges in standardizing HRD assessment, including variability in testing approaches and interpretation thresholds. Additionally, emerging strategies for optimizing HRD-targeted therapies are discussed, emphasizing novel biomarkers and therapeutic combinations. By consolidating current knowledge and advancements, this review provides insights into HRD’s role in cancer biology and its potential for refining personalized treatment approaches.